Licensing status

Publication and contact information

Ophthalmic disease

Ophthalmic disease

Adrenergic receptor a1 (ADRA1); ADRA2; adenylate cyclase 1 (ADCY1; AC1)

Mouse studies suggest antagonizing ADRA1 or stimulating ADRA2 could help treat Stargardt disease. In healthy human and mouse retinas, transcriptome analyses identified GPCRs and GPCR signaling genes that were highly expressed in the eye, including isoforms of ADRA2. In a mouse model of Stargardt disease, pretreatment with an ADRA1 antagonist, an ADRA2 agonist or an AC1 inhibitor preserved retinal function by decreasing photoreceptor damage, levels of reactive oxygen species and fluorescent deposits in the retina after damaging light exposure. Next steps could include testing the approaches in additional animal models of retinal diseases.

SciBX 7(1); doi:10.1038/scibx.2014.28
Published online Jan. 9, 2014

Patent and licensing status unavailable

Chen, Y. et al. J. Clin. Invest.; published online Nov. 15, 2013;
Contact: Krzysztof Palczewski, Case Western Reserve University,
Cleveland, Ohio